Asymmetry Capital Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Asymmetry Capital Management’s Portfolio ICPT Stock Details ICPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,918	Closed	-$2.17M	–	45
2018 Q2	$2.17M	Buy	+25,918	New	+$1.9M	2.14%	19
2017 Q3	–	Sell	-29,570	Closed	-$3.58M	–	36
2017 Q2	$3.58M	Buy	+29,570	New	+$3.43M	4.25%	12

Other funds holding ICPT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

AGA

Altrinsic Global Advisors Stamford, Connecticut $2.79B AUM 7.25% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Asymmetry Capital Management's ICPT Position: Q3 2018 in Review

Asymmetry Capital Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q3 2018, closing a stake of 25,918 shares — an estimated $2.17M sold.

Asymmetry Capital Management first reported a position in ICPT in Q2 2017 and held it in 2 quarters. The position peaked at $3.58M in Q2 2017. 175 funds tracked by Wall St. Rank hold ICPT as of Q3 2018.

Asymmetry Capital Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q3 2018 after selling out during the quarter.
Asymmetry Capital Management sold 25,918 Intercept Pharmaceuticals, Inc. shares in Q3 2018, an estimated $2.17M.
Asymmetry Capital Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2017 and held it in 2 quarters.
Asymmetry Capital Management's Intercept Pharmaceuticals, Inc. position peaked at $3.58M in Q2 2017.
175 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q3 2018.

Based on Asymmetry Capital Management's 13F filing for Q3 2018, filed 8 Nov 2018.